85 related articles for article (PubMed ID: 15020841)
21. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
[TBL] [Abstract][Full Text] [Related]
22. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.
Chen SY; Hu SS; Dong Q; Cai JX; Zhang WP; Sun JY; Wang TT; Xie J; He HR; Xing JF; Lu J; Dong YL
Asian Pac J Cancer Prev; 2013; 14(10):6135-40. PubMed ID: 24289639
[TBL] [Abstract][Full Text] [Related]
23. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
Imai Y; Ishikawa E; Asada S; Sugimoto Y
Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404
[TBL] [Abstract][Full Text] [Related]
24. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.
Li Z; Carrier L; Belame A; Thiyagarajah A; Salvo VA; Burow ME; Rowan BG
Breast Cancer Res Treat; 2009 Nov; 118(1):33-43. PubMed ID: 18855134
[TBL] [Abstract][Full Text] [Related]
25. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
26. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.
Sommer A; Hoffmann J; Lichtner RB; Schneider MR; Parczyk K
J Steroid Biochem Mol Biol; 2003 May; 85(1):33-47. PubMed ID: 12798355
[TBL] [Abstract][Full Text] [Related]
27. Hyperglycaemia-induced chemoresistance in breast cancer cells: role of the estrogen receptor.
Zeng L; Zielinska HA; Arshad A; Shield JP; Bahl A; Holly JM; Perks CM
Endocr Relat Cancer; 2016 Feb; 23(2):125-34. PubMed ID: 26647383
[TBL] [Abstract][Full Text] [Related]
28. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
[TBL] [Abstract][Full Text] [Related]
30. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
31. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
32. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
33. Metalloestrogenic effects of cadmium are absent in long-term estrogen-deprived MCF-7 cells: Evidence for the involvement of constitutively activated estrogen receptor α and very low expression of G protein-coupled estrogen receptor 1.
Hirao-Suzuki M; Takeda S; Kodama Y; Takiguchi M; Toda A; Ohara M
Toxicol Lett; 2020 Feb; 319():22-30. PubMed ID: 31689473
[TBL] [Abstract][Full Text] [Related]
34. ERα directly activated the MDR1 transcription to increase paclitaxel-resistance of ERα-positive breast cancer cells in vitro and in vivo.
Shi JF; Yang N; Ding HJ; Zhang JX; Hu ML; Leng Y; Han X; Sun YJ
Int J Biochem Cell Biol; 2014 Aug; 53():35-45. PubMed ID: 24786296
[TBL] [Abstract][Full Text] [Related]
35. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
36. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
37. Genistin attenuates cellular growth and promotes apoptotic cell death breast cancer cells through modulation of ERalpha signaling pathway.
Hwang ST; Yang MH; Baek SH; Um JY; Ahn KS
Life Sci; 2020 Dec; 263():118594. PubMed ID: 33075375
[TBL] [Abstract][Full Text] [Related]
38. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.
Pons DG; Torrens-Mas M; Nadal-Serrano M; Sastre-Serra J; Roca P; Oliver J
Int J Biochem Cell Biol; 2015 Sep; 66():85-94. PubMed ID: 26232188
[TBL] [Abstract][Full Text] [Related]
39. [Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells].
Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ
Ai Zheng; 2006 Aug; 25(8):967-73. PubMed ID: 16965676
[TBL] [Abstract][Full Text] [Related]
40. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
